|1.||Li, Yuan-Jian: 12 articles (03/2011 - 08/2002)|
|2.||Hu, Chang-Ping: 7 articles (03/2011 - 08/2002)|
|3.||Deng, Han-Wu: 5 articles (10/2010 - 08/2002)|
|4.||Li, Dai: 4 articles (07/2009 - 12/2007)|
|5.||Deng, Pan-Yue: 4 articles (09/2005 - 12/2004)|
|6.||Hu, Gao-Yun: 3 articles (12/2008 - 12/2007)|
|7.||Tan, Gui-Shan: 3 articles (05/2005 - 12/2004)|
|8.||Luo, Dan: 2 articles (06/2015 - 12/2007)|
|9.||Peng, Jun: 2 articles (10/2010 - 10/2008)|
|10.||Qin, Xu-Ping: 2 articles (03/2009 - 12/2007)|
|1.||Myocardial Ischemia (Ischemic Heart Diseases)
12/01/2008 - "Our previous studies showed that rutaecarpine (Rut) protected against myocardial ischemia/reperfusion (I/R) injury, which was associated with activation of transient receptor potential vanilloid subtype 1 (TRPV1). "
08/05/2013 - "Rutaecarpine, an active component of the traditional Chinese medicine Tetradium ruticarpum, has been shown to improve myocardial ischemia reperfusion injury. "
06/15/2003 - "In the present study, we examined whether rutaecarpine protects against myocardial ischemia-reperfusion injury in rats and whether the protective effects of rutaecarpine are related to activation of capsaicin-sensitive sensory nerves. "
06/15/2003 - "These results suggest that rutaecarpine protects against myocardial ischemia-reperfusion injury in rats and that the protective effects of rutaecarpine are related to activation of capsaicin-sensitive sensory nerves via activating vanilloid receptors."
08/01/2002 - "Previous investigations have shown that calcitonin gene-related peptide (CGRP) protects against myocardial ischemia-reperfusion injury and that rutaecarpine activates vanilloid receptors to evoke CGRP release. "
07/01/2009 - "4. The results of the present study suggest that the increased cardiac susceptibility to ischaemia-reperfusion injury in SHR is related to decreased plasma CGRP levels and that antihypertensive therapy with rutaecarpine reverses cardiac susceptibility to reperfusion injury by stimulating CGRP release."
07/01/2009 - "The aim of the present study was to determine whether rutaecarpine is able to decrease the susceptibility of hypertensive animals to ischaemia-reperfusion injury by stimulating CGRP release. "
08/05/2013 - "We hypothesized that rutaecarpine also has neuroprotective effects on cerebral ischemia reperfusion injury. "
08/05/2013 - "Neuroprotective effects of rutaecarpine on cerebral ischemia reperfusion injury."
11/10/2015 - "Rutaecarpine and evodiamine selected as β1-AR inhibitor candidates using β1-AR/CMC-offline-UPLC/MS prevent cardiac ischemia-reperfusion injury via energy modulation."
10/18/2013 - "Our results suggest that rutaecarpine analogues may have therapeutic potential for obesity and related metabolic disorders. "
11/20/2009 - "Both mice strains developed obesity, but the obesity was inhibited by the reduced food intake resulting from rutecarpine treatment (0.01%, p<0.01). "
01/01/2008 - "Rutaecarpine is an indolopyridoquinazolinone alkaloid isolated from Evodia rutaecarpa and related herbs, which has shown a variety of intriguing biological properties such as anti-thrombotic, anticancer, anti-inflammatory and analgesic, anti-obesity and thermoregulatory, vasorelaxing activity, as well as effects on the cardiovascular and endocrine systems. "
11/20/2009 - "These results indicate that rutecarpine ameliorates obesity by inhibiting food intake, which involves inhibited expression of the orexigenic neuropeptides NPY and AgRP."
11/20/2009 - "This study explored the inhibitory effect of rutecarpine on feeding and obesity in high-fat-diet-induced (C57BL/6) and leptin-deficient (ob/ob) obese mice. "
|4.||Atopic Dermatitis (Atopic Eczema)
03/01/2011 - "To study the effect of Rutaecarpine on the treatment of atopic dermatitis in mice. "
03/01/2011 - "The animal model of atopic dermatitis treated with Rutaecarpine had higher levels of plasma IFN-gamma level [(68.29 +/- 1.39) pg/mL] than those without treatment [(51.23 +/- 11.45) pg/mL]. "
03/01/2011 - "[Effect and mechanisms of rutaecarpine on treating atopic dermatitis in mice]."
03/01/2011 - "The therapeutic effect of Rutaecarpine on atopic dermatitis-like skin lesions may be taken through inhibiting IgE and IL-4 synthesis and promoting the secretion of IFN-gamma."
03/01/2011 - "The animal model of atopic dermatitis treated with Rutaecarpine had lower levels of plasma IL-4 and IgE [(72.11 +/- 2.13) pg/mL and (69.17 +/- 4.15) ng/mL, respectively] than those without treatment [(95.49 +/- 6.32) pg/mL and (124.42 +/- 11.14) ng/mL, respectively, P < 0.05]. "
|5.||Anaphylaxis (Anaphylactic Shock)
12/01/2004 - "In the present study, the effect of rutaecarpine on cardiac anaphylaxis was examined. "
02/15/2005 - "Involvement of CGRP in the inhibitory effect of rutaecarpine on vasoconstriction induced by anaphylaxis in guinea pig."
02/15/2005 - "The present results suggest that an increase in the release of CGRP during vascular anaphylaxis may be a beneficial compensatory response, and that rutaecarpine inhibits antigen-challenged vasoconstriction, which is related to stimulation of endogenous CGRP release via activation of VR1."
12/01/2004 - "The protective effects of rutaecarpine on cardiac anaphylaxis were abolished by CGRP (8-37), a selective CGRP receptor antagonist. "
|4.||Adenosine Triphosphate (ATP)
|5.||Adenosine Triphosphatases (ATPase)
|7.||TRPV Cation Channels
|8.||Immunoglobulin E (IgE)
|9.||Calcitonin Gene-Related Peptide Receptors (Calcitonin-Gene Related Peptide Receptor)
|1.||Chinese Traditional Medicine (Traditional Chinese Medicine)